Combination of tofacitinib with transplantation of non-cultured epidermal cell suspension vs non-cultured epidermal cell suspension alone in non-segmental vitiligo patches clinically stable for less than 1 year: a randomized controlled trial

All India Institute of Medical Sciences0 个研究点目标入组 0 人开始时间: 待定最近更新: 2024年1月22日

试验速览

暂无简介。

•Adult ( >18 years) patients with non-segmental (generalized, acrofacial, focal) vitiligo clinically stable for <1 (3-12 months) year (VIDA Score +1 or +2)

•1.Children, pregnant or lactating women with vitiligo
•2.Patients with segmental vitiligo
•3.Patients with vitiligo of clinical disease stability >1 year (VIDA score 0 or -1)
•4.Patients with vitiligo of clinical disease stability < 3 months (VIDA score +3 or +4)
•5.Patients with keloidal or bleeding tendency
•6.Patients on topical treatment for last 2 weeks, and on phototherapy/systemic treatment for last 4 weeks
•7.Patients with active tuberculosis / other systemic infection or any other contra-indication to tofacitinib
•8.Patients with latent tuberculosis, who refuse prophylactic anti-tubercular treatment (Patients who have evidence of latent TB may be enrolled if they complete at least 4 weeks of appropriate treatment prior to randomization and agree to complete the remainder of treatment while in the trial)
•9.Vitiligo patch <2.5cm2 or >100cm2

发起方